Asset Details
Do you wish to reserve the book?
Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia
Do you wish to request the book?
Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia
2013
Overview
Gene mutations were found in acute myeloid leukemia (AML) and their importance has been noted. To clarify the importance and stability of mutations, we examined gene mutations in paired samples at diagnosis and relapse of 34 adult AML patients. Five acquired gene mutations were detected at relapse. Of the 45 gene mutations at diagnosis, 11 of them were lost at relapse. The acquired mutations at relapse were all class I mutations as Fms-like tyrosine kinase 3 (
FLT3
) and rat sarcoma viral oncogene homolog (
RAS)
mutations. The disappeared mutations at relapse were 3 of 11 internal tandem duplications of
FLT3 (FLT3-
ITD) (27.3%), 3 of 3
FLT3
tyrosine kinase domain (
FLT3
-TKD) (100%), 3 of 13
Nucleophosmin 1
(23.1%) and 2 of 5
CCAAT/enhancer-binding protein-α
(40%) mutations. However, epigenetics-modifying gene (
DNMT3a
,
TET2 and IDH1/2
) mutations had no change between diagnosis and relapse samples, and may become minimal residual disease marker. The frequency of
FLT3
-ITD at relapse in patients with
DNMT3a
mutation at diagnosis is significantly higher than those in patients without them (
P
=0.001). Moreover, the high frequency of
FLT3
-ITD at relapse is also seen in AML cases that initially present with any epigenetics-modifying gene mutations (
P
<0.001). Our results indicate that epigenetics-modifying gene mutations may cause genetic instability and induce
FLT3
-ITD, leading to resistance to therapy and relapse.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ CCAAT/enhancer-binding protein
/ DNA (Cytosine-5-)-Methyltransferases - genetics
/ DNA-Binding Proteins - genetics
/ fms-Like Tyrosine Kinase 3 - genetics
/ Homology
/ Humans
/ Isocitrate Dehydrogenase - genetics
/ Kinases
/ Leukemia
/ Leukemia, Myeloid, Acute - genetics
/ Medicine
/ Mutation
/ Oncology
/ Proto-Oncogene Proteins - genetics
/ Sarcoma
/ Tyrosine
